Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

A collaborative research team has successfully developed a novel fluorescent probe, SLY (Sialyl Lewis Yellow), capable of ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today thar it has received a Notice ...

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable ...

A hepatocellular carcinoma risk score using routine clinical data outdid the FIB-4 alone in identifying at-risk patients without viral hepatitis or cirrhosis.

Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world ...

Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both ...